Takeda invests in Fate Therapeutics

Tuesday, May 10, 2011 12:22 PM

Japan-based Takeda has made a strategic investment in the U.S.-based Fate Therapeutics, a privately-held firm that specializes in stem cell research, according to Pharma Times.

The investment has been made via the Japanese drugmaker's corporate venture arm, Takeda Ventures, and is designed to expand Takeda’s portfolio in regenerative medicine.

Fate’s first therapeutic candidate is now in phase Ib studies in hematopoietic reconstitution in patients with malignancies such as leukemia and lymphoma.

Takeda says its new partner utilizes "the most advanced biologics and reprogramming technologies for identifying promising points of therapeutic intervention." Fate has secured backing from venture firms and the investment arms of Astellas and Genzyme.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs